Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia

Related Experiment Video

Updated: Dec 5, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.5K

Elizabeth Hewlett1, Monika Toma2, Katherine Sullivan-Reed2

  • 1Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, 3307 N. Broad Street, Philadelphia, PA, United States.

Medicinal Chemistry Research : an International Journal for Rapid Communications on Design and Mechanisms of Action of Biologically Active Agents
|October 19, 2020
PubMed

Insights

Researchers developed a novel allosteric PARP1 inhibitor, molecule 7, to overcome resistance to current cancer therapies. This new compound shows potent anti-cancer activity, offering a promising avenue for personalized medicine in BRCA-deficient cancers.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors are effective in treating BRCA1/2-deficient cancers via synthetic lethality.
  • Existing PARP1 inhibitors face resistance due to competition with NAD+.
  • Allosteric PARP1 inhibitors offer a potential strategy to overcome this resistance.

Purpose of the Study:

  • To explore the structure-activity relationship of the allosteric PARP1 inhibitor 5F02.
  • To identify novel analogs with improved anti-cancer properties.
  • To develop a lead molecule for treating BRCA-deficient cancers.

Main Methods:

  • High-throughput screening identified 5F02 as an allosteric PARP1 inhibitor.
  • Analogs of 5F02 were synthesized with structural variations.
  • Structure-activity relationship studies were conducted.
  • Anti-clonogenic activity was assessed in BRCA-deficient and proficient leukemia cells.

Main Results:

  • Lead molecule 7 demonstrated potent anti-clonogenic activity against BRCA-deficient NALM6 leukemia cells.
  • Molecule 7 exhibited a significant therapeutic index over BRCA-proficient cells.
  • 5F02 showed greater potency and synergy with olaparib in preliminary assays.

Conclusions:

  • Allosteric PARP1 inhibition is a viable strategy to overcome resistance to current cancer therapies.
  • Molecule 7 represents a promising lead compound for developing new treatments for BRCA-deficient cancers.
  • Further research into allosteric PARP1 inhibitors could advance personalized cancer medicine.
Keywords:
AllostericBRCAHistone 4PARP1Synthetic Lethality

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.3K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K